Our leadership

Shlomi Pilo brings decades of commercial, operating and business-development experience to Raphael Pharmaceutical. His background includes senior sales and marketing leadership and the development of international business relationships across multiple markets. Prior to leading Raphael, he spent many years in sales and marketing leadership at Alle Processing Corporation during a period of substantial company growth and also built experience representing manufacturers and developing cross-border commercial relationships. At Raphael, Pilo leads corporate strategy, business development and the company’s effort to translate its cannabinoid research experience into disciplined scientific and commercial opportunities.

Uri Tadelis brings experience across corporate finance, investment strategy, international transactions and financial technology. His professional background has included work with institutions, banks, family offices and private clients across foreign exchange, commodities, structured investments and cross-border financial opportunities, as well as leadership in financial and technology ventures. At Raphael, Tadelis is responsible for financial oversight, reporting, capital planning and supporting the company’s investor and corporate-finance strategy as it advances its next stage of scientific and commercial development. His profile emphasizes disciplined financial stewardship, transparent public-company reporting and the connection between capital planning and Raphael’s operating priorities.